Ocular Therapeutix is betting that a partial safety readout, combined with earlier efficacy data, will be enough to get its wet AMD drug candidate in front of the FDA by late 2026. The company laid out that strategy Monday, and the implications ripple across a few different groups: patients, rival drugmakers, and the company’s own pipeline priorities. The core move is a New Drug Application submission for AXPAXLI, planned for the fourth quarter of 2026.
That filing will lean on the SOL-1 efficacy and safety results plus interim safety data from the ongoing SOL-R trial. The FDA has signed off on that approach.
That alignment is the key fact here — it means the agency sees the same logic Ocular does. It shortens the wait. And the company is using the 505(b)(2) regulatory pathway.
That choice can shave up to 60 days off the FDA review clock. It’s a procedural detail, but one with real consequences.
Faster review means a potential decision sooner, assuming the data holds up. For patients with wet age-related macular degeneration, that could mean a new treatment option arrives earlier than a standard timeline would allow. But the SOL-R trial is far from over.
It remains masked through Week 96. The trial now includes a new secondary endpoint: testing whether AXPAXLI is superior to aflibercept at that two-year mark. Topline results from that comparison are expected in the first quarter of 2028.
That’s a long horizon. If the drug gets approved before that data drops, the label will reflect what the FDA knows now — not what the superiority endpoint might later show.
A positive readout in 2028 could then support broader global adoption and a stronger competitive position. The SOL-1 data also reshaped the company’s diabetic retinopathy program. That program has been streamlined.
The HELIOS-3 trial is now the priority — a potential single registrational trial testing once-yearly dosing of AXPAXLI. That is a direct consequence of the SOL-1 results.
The company is focusing its resources on what it sees as the strongest shot at another indication. For competitors, the message is clear. Ocular is pushing for a best-in-disease label in wet AMD.
Aflibercept is the current benchmark in the superiority endpoint. If AXPAXLI beats it at 96 weeks, that would be a direct challenge to an established therapy. Even without that data, the NDA submission itself signals momentum.
Regeneron and other players in the space will be watching the FDA review timeline closely. For investors, the day was about seeing the roadmap.
The company laid out a sequence: NDA submission in Q4 2026, potential accelerated review, then the longer wait for the SOL-R superiority readout. The HELIOS-3 trial in diabetic retinopathy adds another potential catalyst, but that program is earlier stage. The calculus is that a single registrational trial could suffice for that indication, which would be efficient — if the data delivers.
The FDA alignment is the foundation of the whole plan. Without that, the NDA timeline would be uncertain.
With it, Ocular has a clear target. The company is betting that the combination of SOL-1 and interim SOL-R safety data tells a complete enough story for approval. The SOL-R trial will keep running, generating the longer-term evidence that could define the drug’s ultimate place in the market.
For now, the clock starts on the 505(b)(2) review.
